Biodesix Announces Third Quarter 2026 Results and Highlights
Globe Newswire•05/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 revenue $24.0 million, up 10% year over year
- ➤Diagnostic Testing revenue $23.0 million, up 16%; test volumes rose 24% to 19,400
- ➤Net loss $8.0 million, improved 8%; Adjusted EBITDA loss $3.9 million, improved 16%
- ➤Full-year 2026 revenue guidance revised to $101 million-$103 million
- ➤Digital Diagnostics radiomics-based lung nodule test commercial availability anticipated in 2028
Expert Statements
Scott Hutton, Chief Executive Officer of Biodesix
“Biodesix delivered another quarter of year-over-year growth, with total revenue increasing 10%, Diagnostic Testing revenue increasing 16%, test volumes increasing 24%, and gross margin remaining strong at 81%.”
Scott Hutton, Chief Executive Officer of Biodesix
“However, our growth was below our expectations, and we understand the principal drivers: fewer contributing sales representatives than planned limited new physician and account growth; greater-than-anticipated seasonality, primarily in primary care, reduced ordering frequency among otherwise stable base customers; and delays in external customer dependencies postponed the start of Development Services projects and the associated revenue recognition.”
Scott Hutton, Chief Executive Officer of Biodesix
“The factors that impacted the quarter were largely execution and timing related rather than a change in demand, clinical utility, or market opportunity.”
Scott Hutton, Chief Executive Officer of Biodesix
“We have identified the drivers, taken corrective actions, and entered the fourth quarter with a larger sales organization positioned for improved execution.”
Scott Hutton, Chief Executive Officer of Biodesix
“Early fourth-quarter trends indicate accelerating new customer acquisition, continued growth across our established customer base, and broader physician engagement.”
Scott Hutton, Chief Executive Officer of Biodesix
“October produced our strongest month of new physician acquisition this year.”
Scott Hutton, Chief Executive Officer of Biodesix
“We also strengthened our long-term position in lung diagnostics through meaningful strategic progress; highlights include CHEST recognition of biomarker-guided lung nodule management, our expansion into multimodal Digital Diagnostics, and complementary MRD programs.”
Scott Hutton, Chief Executive Officer of Biodesix
“As a result of this progress and the corrective actions implemented, we believe Biodesix is positioned to enter 2027 from a stronger strategic position than ever before.”
Delivered total revenue of $24.0 million, an increase of 10% year over year
Grew Diagnostic Testing revenue 16% year over year, with test volumes increasing 24%
Get started
Create a free account to read the full story.